Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Bladder cancer is the fifth most common cancer in Canada and there has been relatively
little progress in altering its clinical course over the last three decades. One of the
major problems identified in the management of this disease, is under staging of muscle
invasive disease which can lead to suboptimal treatment and outcomes. PET-CT has the
potential to more accurately stage MIBC than standard CT by detecting pelvic adenopathy
and/or distant sites of disease that may not be found on standard imaging. In the former
situation, more aggressive therapy with extended lymph node dissection and/or neoadjuvant
chemotherapy prior to cystectomy can be offered. While in the latter situation patients can
be spared the morbidity of a cystectomy performed in a setting of metastatic disease. This
study will address whether PET-CT adds a clinically meaningful difference in care.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society